The drug received accelerated approval for use in children aged 8 to 17 with recently diagnosed stage 3 type 1 diabetes to delay disease progression.
Observers are watching the situation closely for further developments.
More details are likely to emerge as the situation continues to develop.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources: